Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A localized form of dystrophic epidermolysis bullosa characterized by blisters confined primarily to the hands and feet (acral form) or to the pretibial region (pretibial form). Nail dystrophy or loss is common and may be an isolated finding (nail only form). This disease can be inherited via autosomal dominant or autosomal recessive inheritance.
2 FDA-approved treatments are available for localized dystrophic epidermolysis bullosa, including Prademagene zamikeracel (zevaskyn, approved 2025) and beremagene geperpavec-svdt (VYJUVEK, approved 2023).
Brand Name | Generic Name | Mechanism | Approved | Market Status |
|---|---|---|---|---|
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for localized dystrophic epidermolysis bullosa.
104 publications have been identified in PubMed for localized dystrophic epidermolysis bullosa. Kisho has analyzed 56 by research type. Research spans Review / Meta-Analysis (25%), Basic Science / Preclinical (23%), and Clinical Trial Publication (21%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 14 | 25% |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 8:41 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
zevaskyn |
Prademagene zamikeracel |
— |
2025 |
Available |
VYJUVEK | beremagene geperpavec-svdt | — | 2023 | Available |
Gene therapy approaches for localized dystrophic epidermolysis bullosa have been reported in the published literature.
View trials for localized dystrophic epidermolysis bullosa
Laboratory research |
13 |
23% |
Clinical study results | 12 | 21% |
Disease patterns and progression | 12 | 21% |
Patient case studies | 4 | 7% |
New treatment approaches | 1 | 2% |
Turner BA (2026). [PMID: 41332251](https://pubmed.ncbi.nlm.nih.gov/41332251/). *Genome Biol Evol*. [Basic Science / Preclinical]
Heppell C (2026). [PMID: 41637086](https://pubmed.ncbi.nlm.nih.gov/41637086/). *JAMA Dermatol*. [Review / Meta-Analysis]
Lanza G (2026). [PMID: 41946854](https://pubmed.ncbi.nlm.nih.gov/41946854/). *J Clin Sleep Med*. [Clinical Trial Publication]
Bighetti S (2025). [PMID: 40844377](https://pubmed.ncbi.nlm.nih.gov/40844377/). *Dermatol Reports*. [Case Report / Case Series]
Nyström A (2025). [PMID: 40061239](https://pubmed.ncbi.nlm.nih.gov/40061239/). *JID Innov*. [Review / Meta-Analysis]
Patra P (2025). [PMID: 41523446](https://pubmed.ncbi.nlm.nih.gov/41523446/). *Cureus*. [Case Report / Case Series]
Primerano A (2025). [PMID: 41277647](https://pubmed.ncbi.nlm.nih.gov/41277647/). *Eur J Dermatol*. [Case Report / Case Series]
Schmid CM (2025). [PMID: 39668183](https://pubmed.ncbi.nlm.nih.gov/39668183/). *Eur J Hum Genet*. [Basic Science / Preclinical]
Lisińska W (2025). [PMID: 40724842](https://pubmed.ncbi.nlm.nih.gov/40724842/). *Int J Mol Sci*. [Review / Meta-Analysis]
Robinson JF (2025). [PMID: 38697337](https://pubmed.ncbi.nlm.nih.gov/38697337/). *Am J Obstet Gynecol*. [Clinical Trial Publication]